knowledge -WSS

knowledge

author：entertainment 2025-10-01 01:00:38 - browse：52

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Slovenia has suffered its worst

WSS

'Brian's Song' at 50 still offers lessons about cancer for today

Pregnant women don't need prenatal multivitamins, study concludes

How CRISPR works, explained in two minutes

St. Louis police protesters begin picking up checks in $4.9 million settlement

McConnell is warmly embraced by Kentucky Republicans amid questions about his health

Ozempic has benefits for kidney disease as well as diabetes

focus

knowledge

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Doctors are clamoring for more clarity on Paxlovid prescribing

Peter Hotez and the public health issue of online harassment

A new approach to psychiatric drug development

State Dept. review finds Biden bears some blame for Afghanistan failures

$1 billion proposal to grow Boston, Massachusetts biotech

Continuity nursing helped my family in our darkest PICU moments

Paxlovid rebound happens. Why and to whom are still a mystery

What does generative AI mean for health care? We asked experts

Pregnant women don't need prenatal multivitamins, study concludes

explore

Longer MASH drug regimen improved liver, Akero study finds

State of the Union pitch: Bigger Medicare drug price negotiations

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

Florida health officials providing scant details on measles cases

Biden's 'march

McConnell is warmly embraced by Kentucky Republicans amid questions about his health

focus

Wikipedia

knowledge

focus